Stay updated with breaking news from Johnson Amp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biologics innovators typically take a lifecycle approach to developing new indications and formulations of their prescription drugs, especially when biosimilar competition is on the horizon.
Don't fall for the siren call of unreasonably high dividends.
Johnson & Johnson's recent announcement heralds a promising breakthrough in combatting dengue fever, often known as "breakbone fever" due to the intense pain it causes. These optimistic findings emerge from preliminary results in a clinical trial, highlighting the potential of a dengue prevention pill.
Johnson & Johnson (NYSE:JNJ – Free Report) – Investment analysts at Leerink Partnrs raised their FY2023 earnings per share estimates for shares of Johnson & Johnson in a report issued on Wednesday, October 18th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of $10.10 for the year, up […]
S&P 500 closes almost unchanged